KALA BIO Secures $12.5 Million Funding to Advance Innovative Eye Disease Therapies

KALA BIO, a pioneering clinical-stage biopharmaceutical company focused on developing cutting-edge therapies for rare and severe eye diseases, has recently secured $12,500,000 in funding. Inspired by the majestic Kalalau trail along Hawaii's Na Pali Coast, KALA BIO's mission is deeply rooted in innovation and a commitment to transforming eye disease treatment. The company's lead product candidate, KPI-012, harnesses the power of its proprietary mesenchymal stem cell secretome (MSC-S) platform to potentially address impaired corneal healing in conditions like persistent corneal epithelial defect (PCED). This funding will further support KALA BIO's efforts in advancing its groundbreaking therapies to combat rare corneal diseases that threaten vision, such as Limbal Stem Cell Deficiency, while also exploring solutions for retinal degenerative diseases like Retinitis Pigmentosa and Stargardt Disease. With Orphan Drug and Fast Track designations from the FDA, KALA BIO is at the forefront of revolutionizing eye disease treatment. To learn more about KALA BIO and its innovative approach, visit www.kalarx.com.